U.S. STERILE INJECTABLES MARKET ANALYSIS

U.S. Sterile Injectables Market, By Molecule Type (Large Molecule and Small Molecule), By Drug Type (Monoclonal Antibody (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, and Others), By Therapeutic Application (Cancer, Metabolic Disorder, Cardiovascular Diseases, Infectious Diseases, Musculoskeletal Disorders, and Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Published In : Nov 2024
Code : CMI4961
Pages :154
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Takeaways from Analyst

The U.S. sterile injectables market growth is driven by the rising prevalence of chronic diseases such as cancer, infections and autoimmune diseases that require drug administration through injectables. Biologics and biosimilars are dominating the market and their uptake continue to rise. Furthermore, the complexity of drug molecules is increasing with more specialty drugs entering the pipeline, which will boost the U.S. sterile injectables industry.

The market offers opportunities for contract manufacturing as larger players are outsourcing production to CMOs. Outsourcing injectable production helps optimize manufacturing capacity and focus on core competencies.

The North-Eastern region in the U.S. dominates due to the concentration of pharmaceutical companies while the Western region is witnessing faster growth led by biosimilar uptake in cancer and immune-oncology.